Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.63 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.63 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.63 |
| ▸ | JAK1 | P23458 | 17/20 | 0.47 |
| ▸ | JAK2 | O60674 | 7/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1504709 | 0.98 | AURKA (0.61) | AURKAAURKBINCENPTPX2JAK1 | |
| SCHEMBL1504356 | 0.79 | AURKB (0.39) | AURKAAURKBINCENPTPX2JAK1 | |
| SCHEMBL1504408 | 0.78 | JAK2 (0.57) | AURKAAURKBINCENPTPX2JAK2 | |
| SCHEMBL31061291 | 0.77 | AURKB (1.00) | AURKAAURKBINCENPTPX2JAK1 | |
| SCHEMBL2239177 | 0.77 | AURKB (1.00) | AURKAAURKBINCENPTPX2JAK1 | |
| SCHEMBL30557126 | 0.72 | BRD4 (0.55) | AURKAAURKBINCENPTPX2JAK1 | |
| SCHEMBL21958476 | 0.70 | JAK1 (0.65) | AURKAAURKBINCENPTPX2JAK1 | |
| SCHEMBL30557210 | 0.69 | PIK3CD (0.58) | AURKAAURKBINCENPTPX2JAK1 | |
| SCHEMBL12472076 | 0.69 | ALDH1A1 (0.43) | AURKBJAK2RPS6KA3JAK3 | |
| SCHEMBL1504261 | 0.69 | ALDH1A1 (0.43) | AURKBJAK2RPS6KA3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574863-A | Heterocyclic compounds as JANUS kinase inhibitors | BIOCRYST PHARM INC | 2012-07-11 | — | — | CN | claimed |
| EP-2470537-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-07-04 | — | — | EP | claimed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | claimed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | claimed |
| CN-102574863-A | Heterocyclic compounds as JANUS kinase inhibitors | BIOCRYST PHARM INC | 2012-07-11 | — | — | CN | disclosed |
| EP-2470537-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | AURKA 212/4885AURKB 406/4885INCENP 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.